Use of idelalisib plus ofatumumab in the frontline treatment of chronic lymphocytic leukaemia (CLL) is effective, yielding high overall response rate, although this is counterbalanced by significant toxicities, according to efficacy data from a phase II trial.
Traffic air pollution exerts a negative effect on foetal development, suggests a new study which shows that long term exposure of pregnant mothers to pollutants, such as particulate matter and nitrogen oxides, leads to higher risks of low birth weight (LBW) at term.
Blood pressure (BP) readings appeared to be similar regardless of whether BP measurements were attended or unattended by staff, nor were CV outcomes different between the two techniques, according to a post hoc survey on participants following the SPRINT* trial.
In the first-line treatment of Philadelphia chromosome-positive chronic myeloid leukaemia (CML), patients presenting BCR-ABL1 transcript levels ≤10 percent at 3 months are more likely to achieve major molecular response at 12 months with faster response rate compared with those who have transcript levels >10 percent, according to ≥12 months of follow-up data from the BFORE* trial.
A recent study presented at the 2017 San Antonio Breast Cancer Symposium (SABCS) showed that acupuncture is effective in reducing aromatase inhibitor–induced joint symptoms among breast cancer patients.
Treatment with defibrotide is safe and effective for patients with veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), following either allogeneic or autologous haematopoietic stem cell transplant (HSCT), according to the results of a study presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exhibition in Atlanta, Georgia.
Adding trastuzumab to standard adjuvant chemotherapy does not improve survival or reduce recurrence in patients with early-stage breast cancer expressing low levels of HER2, according to results of a National Surgical Adjuvant Breast and Bowel Project study reported at the 2017 San Antonio Breast Cancer Symposium (SABCS).
New drug applications approved by US FDA as of 1 - 15 December 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Once-weekly subcutaneous administration of the bispecific humanized monoclonal antibody emicizumab successfully prevented or reduced bleeds with a favourable safety profile in paediatric patients with haemophilia A with inhibitors in the phase III HAVEN-2* trial, confirming the findings of a previous interim analysis.
Combining the DASH (Dietary Approaches to Stop Hypertension) diet with low sodium intake reduces systolic blood pressure (SBP) in individuals with pre- and stage 1 hypertension, with progressively higher reductions at greater levels of baseline SBP, a recent study has shown.
At a symposium during the 25th Congress of the Obstetrical and Gynaecological Society of Malaysia in Kuala Lumpur, Professor Susan Davis discussed the unique implications of women living decades beyond menopause, and how healthcare professionals can best manage menopausal symptoms in the short and long term.